Johnson & Johnson's involvement in developing treatments for conditions like FNAIT through partnerships showcases its strategy to lead in healthcare innovation. While the impact on its stock might be less pronounced due to its larger market cap and diversified portfolio, such collaborations reinforce its position in the healthcare sector and could lead to positive market reactions.

The announcement of a significant partnership with a healthcare giant like Johnson & Johnson typically leads to positive investor sentiment, as it suggests potential for future revenue growth and market expansion. This collaboration specifically targets a niche but critical area of maternal and fetal health, highlighting Rallybio's commitment to addressing unmet medical needs.